Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans
NCT ID: NCT02340845
Last Updated: 2015-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
100 participants
INTERVENTIONAL
2014-05-31
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
NCT06063486
Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
NCT00365209
Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue
NCT01294072
Celecoxib in Treating Patients With Precancerous Lesions of the Mouth
NCT00014404
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
NCT01014546
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients suffering from late stage breast, lung, colon, cervical, ovarian, and uterine cancers in stages III and IV, with tissue proof of well-documented malignancies, whether by tissue biopsies and/or laparatomy or thoracotomy and have not been helped by conventional radiation therapy and/or chemotherapies are eligible for this study. Additionally the following conditions must be met:
1. Patient's age is between 18 and 85 years.
2. Patient is not taking anticoagulants or on antiplatelet therapy.
3. Patient does not have a history of abdominal fistula, gastroenteral perforation, peptic ulcer diseases, or intra-abdominal abscess within 6 months prior to study enrollment.
4. Patient has not had major surgery within 4 weeks prior to study enrollment. Patients who have not recovered from adverse events due to surgery performed more than 4 weeks earlier are not eligible for this study.
5. Patient does not currently have uncontrolled hypertension, diabetes, or clinically significant cardiac arrhythmia.
6. Patient does not have an allergic reaction to Bromelain or pineapple-containing products.
7. Female patients should not be pregnant or breastfeeding.
8. Patient's platelet counts must be greater than 100,000/mL.
9. Patient's hemoglobin must be greater than 9.0 g/dL.
10. Patient does not have significant abnormal hepatic and/or renal function.
11. Patient's tumors are measurable; between 0.2 - 10 cm in size and number between 1 - 15. All measurable tumors that have spread to the bones, liver, lung, kidney, and abdomen will be included in the data analysis.
Patients with following conditions will be excluded from the study:
1. Hemoglobulin less than 9 g/dL and WBC less than 4.0 k/µL.
2. Platelet count less than 100,000/µL.
3. INR greater than 1.5
4. Patient currently taking therapeutic doses of warfarin or anti anti-platelet agents.
5. Patient has a history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within 6 months prior to study enrollment.
6. Patient currently has uncontrolled hypertension, diabetes, or clinically significant cardiac arrhythmia.
7. Patient who had major surgery performed within 4 weeks prior to entering the study; and patients who have not recovered from adverse events due to surgery performed more than 4 weeks earlier.
8. Patient with a history of allergic reaction to Bromelain or pineapple-containing products.
9. Female patients who are pregnant or breastfeeding.
10. Patient with tumors that are widely spread in the chest and abdomen that cannot be measured by CT scan.
Patients who are eligible for this study will be randomly assigned to either the low dose group or the high dose group by a coin toss. Each study subject will be assigned a patient number for the purpose of this study.
2. Drug Dosage and Schedule
High Dose Group-The oral dose of Bromelain (50 mg/kg/day) is extrapolated from in vivo animal studies, and determined to be safe by a Safety study on healthy human subjects (see Section VII-A). For this clinical investigation, the High Dose group will be given Bromelain at 50 mg/kg/day, to a maximum of 2400 mg/day (divided into 2 doses/day of 1200 mg/dose)
Low Dose Group - Low Dose group will be given 10 mg/kg/day, to a maximum of 500 mg/day (divided into 2 doses/day of 250 mg/dose).
The number of patients suffering from well-documented malignancies to be assigned to this group will be at least 30: with the combination of mixed types carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, hepatic, bladder, lymphoma, melanoma, and so forth. These patients will be given Bromelain at 500 mg/day, divided into two doses of 250 mg/dose and taken with meals.
High Dose Group - The dose will be at 50 mg/kg/day, The number of patients suffering from well-documented malignancies with be at least 60: with the combination of mixed types carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, hepatic, bladder, lymphoma, melanoma, and so forth. These patients will be given Bromelain at 2400 mg/day, divided into two doses of 1200 mg/dose and taken with meals.
3. Duration and Route of Administration Study subjects will be provided with Bromelain for oral administration. The containers will be clearly labeled (see Section V-E). Bromelain will be taken orally twice daily with meals. On their biweekly visits to the Doctor's Office, the Study patients will be provided with enough doses for two weeks. The study patients are required to keep a journal of the daily doses they take and any side effects they experience.
The study patients will be evaluated using blood tests and CT scans at six months for signs of disease progression. If the disease did not progress, then treatment will continue and the patient will be evaluated every six months thereafter until the investigator determines otherwise. If the disease did progress, then the patient will be taken off the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bromalian 10 mg/kg/day
The number of patients suffering from well-documented malignancies to be assigned to this group will be at least 30: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 500 mg/day, divided into two doses of 250 mg/dose and taken with meals.
Bromelain and Comosain
Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
Bromalian 50mg/kg/day
The number of patients suffering from well-documented malignancies with be at least 60: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 2400 mg/day, divided into two doses of 1200 mg/dose and taken with meals.
Bromelain and Comosain
Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bromelain and Comosain
Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patient's age is between 18 and 85 years.
2. Patient is not taking anticoagulants or on antiplatelet therapy.
3. Patient does not have a history of abdominal fistula, gastroenteral perforation, peptic ulcer diseases, or intra-abdominal abscess within 6 months prior to study enrollment.
4. Patient has not had major surgery within 4 weeks prior to study enrollment. Patients who have not recovered from adverse events due to surgery performed more than 4 weeks earlier are not eligible for this study.
5. Patient does not currently have uncontrolled hypertension, diabetes, or clinically significant cardiac arrhythmia.
6. Patient does not have an allergic reaction to Bromelain or pineapple-containing products.
7. Female patients should not be pregnant or breastfeeding.
8. Patient's platelet counts must be greater than 100,000/mL.
9. Patient's hemoglobin must be greater than 9.0 g/dL.
10. Patient does not have significant abnormal hepatic and/or renal function.
11. Patient's tumors are measurable; between 0.2 - 10 cm in size and number between 1 - 15. All measurable tumors that have spread to the bones, liver, lung, kidney, and abdomen will be included in the data analysis.
Exclusion Criteria
1. Hemoglobulin less than 9 g/dL and WBC less than 4.0 k/µL.
2. Platelet count less than 100,000/µL.
3. INR greater than 1.5
4. Patient currently taking therapeutic doses of warfarin or anti anti-platelet agents.
5. Patient has a history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within 6 months prior to study enrollment.
6. Patient currently has uncontrolled hypertension, diabetes, or clinically significant cardiac arrhythmia.
7. Patient who had major surgery performed within 4 weeks prior to entering the study; and patients who have not recovered from adverse events due to surgery performed more than 4 weeks earlier.
8. Patient with a history of allergic reaction to Bromelain or pineapple-containing products.
9. Female patients who are pregnant or breastfeeding.
10. Patient with tumors that are widely spread in the chest and abdomen that cannot be measured by CT scan.
Patients who are eligible for this study will be randomly assigned to either the low dose group or the high dose group by a coin toss. Each study subject will be assigned a patient number for the purpose of this study.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oeyama-Moto Cancer Research Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benedict Liao, M.D.
Role: PRINCIPAL_INVESTIGATOR
OeyamaMoto Cancer research Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
OeyamaMoto Cancer Research Foundation
West Covina, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
116911
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.